Observational studyMedicine2026

Single-center experience with Romiplostim N01 for the management of severe persistent cancer therapy-induced thrombocytopenia in lung cancer: Insights and outcomes.

Changjian Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.